Literature DB >> 402522

Pseudomonas mastoiditis.

W L Meyerhoff, G A Gates, P J Montalbo.   

Abstract

Opportunistic infections of the external auditory canal or the middle ear due to Pseudomonas aeruginosa occurring in patients with low resistance to infection have a 35 percent mortality rate. Once the process extends into the pneumatized temporal bone, eradication becomes more difficult and the mortality rate increases to 72 percent because of the high incidence of involvement of cranial nerves, adjacent intracranial vessels, and meningitis. Treatment is directed towards the underlying condition, administration of systemic carbenicillin and gentamicin, topical colistin therapy, and judicious surgical debridement. Pseudomonas vaccine may be of help. Fifteen cases are presented. Nine follow the pattern of malignant external otitis and six began as a primary acute otitis media.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402522     DOI: 10.1288/00005537-197704000-00003

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Malignant pseudomonas external otitis.

Authors:  J E Edwards; W A Combs; L B Guze
Journal:  West J Med       Date:  1979-09

2.  Osteomyelitis of the temporal bone and skull base in diabetes resulting from otitis media.

Authors:  S Merchant; D M Vernick
Journal:  Skull Base Surg       Date:  1992

3.  Malignant otitis externa.

Authors:  R Mills
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-15

4.  Treating malignant otitis with oral ciprofloxacin.

Authors:  S A Hickey; G R Ford; A F O'Connor; S J Eykyn; P H Sönksen
Journal:  BMJ       Date:  1989-08-26

5.  Staphylococcal malignant external otitis.

Authors:  P Bayardelle; M Jolivet-Granger; D Larochelle
Journal:  Can Med Assoc J       Date:  1982-01-15       Impact factor: 8.262

6.  Pseudomonas osteitis causing cranial nerve palsies.

Authors:  A H Schapira; A N Gale
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.